These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2496877)

  • 1. Methylprednisolone and Graves' ophthalmopathy.
    Dandona P; Havard CW; Mier A
    BMJ; 1989 Mar; 298(6676):830. PubMed ID: 2496877
    [No Abstract]   [Full Text] [Related]  

  • 2. Methylprednisolone in the treatment of exophthalmos.
    Garber MI
    Lancet; 1966 Apr; 1(7444):958-60. PubMed ID: 4160651
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy.
    Macchia PE; Bagattini M; Lupoli G; Vitale M; Vitale G; Fenzi G
    J Endocrinol Invest; 2001 Mar; 24(3):152-8. PubMed ID: 11314743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
    Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early effects of methylprednisolone infusion on serum cystatin C in patients with severe Graves' ophthalmopathy.
    Manetti L; Genovesi M; Pardini E; Grasso L; Lupi I; Linda Morselli L; Pellegrini G; Martino E
    Clin Chim Acta; 2005 Jun; 356(1-2):227-8. PubMed ID: 15936323
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic responses to corticosteroids in Graves' ophthalmopathy.
    Chang TC; Kao SC; Hsiao YL; Lu CP; Huang KM; Tzeng SS
    J Formos Med Assoc; 1996 Nov; 95(11):833-8. PubMed ID: 8990770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.
    Kendall-Taylor P; Crombie AL; Stephenson AM; Hardwick M; Hall K
    BMJ; 1988 Dec; 297(6663):1574-8. PubMed ID: 2906260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of rituximab treatment for exophthalmos, myxedema, and osteoarthropathy syndrome resistant to corticosteroids due to Graves' disease: a case report.
    Ferreira-Hermosillo A; Casados-V R; Paúl-Gaytán P; Mendoza-Zubieta V
    J Med Case Rep; 2018 Feb; 12(1):38. PubMed ID: 29448964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
    Myśliwiec J; Kretowski A; Topolska J; Siewko K; Jakubczyk D; Szelachowska M; Mikita A; Kinalska I
    Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
    Brauer VF; Scholz GH
    Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Malignant exophthalmos treated with methylprednisolone acetate].
    Roelsen E; Skjoerboek-Olesen O
    Ugeskr Laeger; 1968 Jan; 130(1):13-5. PubMed ID: 5694738
    [No Abstract]   [Full Text] [Related]  

  • 15. [The assessment of urinary glycosaminoglycans (GAG) excretion during therapy of patients with progressive Graves' ophthalmopathy].
    Pilarska K; Kulig G; Krzystolik Z
    Pol Arch Med Wewn; 2001 Feb; 105(2):139-44. PubMed ID: 11505748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoids in the medical management of Graves' ophthalmopathy.
    Hart RH; Perros P
    Minerva Endocrinol; 2003 Sep; 28(3):223-31. PubMed ID: 14605604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.
    Bartalena L; Marcocci C; Chiovato L; Laddaga M; Lepri G; Andreani D; Cavallacci G; Baschieri L; Pinchera A
    J Clin Endocrinol Metab; 1983 Jun; 56(6):1139-44. PubMed ID: 6341388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.
    Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
    Thyroid; 2002 Jul; 12(7):603-8. PubMed ID: 12193305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylprednisolone increases plasma leptin levels in Graves' hyperthyroidism patients with active Graves' ophthalmopathy.
    Song YM; Lee WJ; Chen MD; Kao CH; Sheu WH
    Horm Metab Res; 2000 Jul; 32(7):277-82. PubMed ID: 10965934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum Fas in patients with Graves' ophthalmopathy as a marker of activity of the ocular inflammatory infiltration].
    Myśliwiec J; Kretowski A; Stepień A; Okłota M; Kinalska I
    Pol Merkur Lekarski; 2004 Oct; 17(100):368-70. PubMed ID: 15690704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.